Tirzepatide for the treatment of metabolic dysfunction-associated steatohepatitis with liver fibrosis: results of the SYNERGY-NASH phase 2 trial - Loomba, R; Hartman, M; Lawitz, E J; Vuppalanchi, R; Boursier, J; Bugianesi, E; Yoneda, M; Behling, C; Cummings, O W; Tang, Y; Brouwers, B; Robins, D; Nikooie, A; Bunck, M C; Haupt, A; Sanyal, A J; Perakakis, N (Diabetologie und Stoffwechsel, 2025)